Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Large Drop in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a significant drop in short interest in March. As of March 31st, there was short interest totaling 706,973 shares, a drop of 21.4% from the March 15th total of 899,445 shares. Currently, 9.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 733,194 shares, the short-interest ratio is currently 1.0 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Avalon GloboCare in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Avalon GloboCare Stock Performance

ALBT opened at $0.42 on Friday. The company has a fifty day moving average price of $0.68 and a two-hundred day moving average price of $1.26. Avalon GloboCare has a 52 week low of $0.34 and a 52 week high of $4.74. The firm has a market capitalization of $3.45 million, a PE ratio of -0.12 and a beta of 0.10.

Avalon GloboCare (NASDAQ:ALBT) last announced its quarterly earnings results on Monday, March 30th. The company reported $0.46 earnings per share for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.